EHA 2022 | Real-world treatment patterns of patients with low-risk MDS reinitiating ESAs
Guillermo Garcia-Manero
• 10 Jun 2022
Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, comments on a study investigating the real-world treatment patterns and clinical outcomes of patients with low-risk myelodysplastic syndromes (MDS) who discontinued and reinitiated erythropoietin stimulating agent (ESA) therapy, highlighting the Phase III COMMANDS study comparing luspatercept with epoietin alfa in the frontline setting (NCT03682536). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
